Difference between revisions of "Part:BBa K3672002"
Line 17: | Line 17: | ||
<partinfo>BBa_K3672002 parameters</partinfo> | <partinfo>BBa_K3672002 parameters</partinfo> | ||
<!-- --> | <!-- --> | ||
+ | |||
+ | ===References=== | ||
+ | <html> | ||
+ | <br> | ||
+ | <ol type="1"> | ||
+ | <li>Chiang, T. M. (2000). A Synthetic Nonapeptide Derived from the Sequence of a Platelet Type I Collagen Receptor Inhibits Type I Collagen-Mediated Platelet Aggregation. The American Journal of the Medical Sciences, 320(6), 362–367. doi:10.1097/00000441-200012000-00002 | ||
+ | <li>Wahyudi H, Reynolds AA, Li Y, Owen SC, Yu SM. Targeting collagen for diagnostic imaging and therapeutic delivery. J Control Release. 2016;240:323-331. doi:10.1016/j.jconrel.2016.01.007 |
Latest revision as of 06:39, 26 October 2020
CILY,collagen I targeting probe
CILY possessed inhibitory activity on type I collagen-induced platelet aggregation and the release of ATP. As recorded, it has a higher binding affinity (Kd:10nM) to collagen type I than the modified version, SILY, but the modification allowed dermatan sulfate to be conjugated to the terminus of the peptide.
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
References
- Chiang, T. M. (2000). A Synthetic Nonapeptide Derived from the Sequence of a Platelet Type I Collagen Receptor Inhibits Type I Collagen-Mediated Platelet Aggregation. The American Journal of the Medical Sciences, 320(6), 362–367. doi:10.1097/00000441-200012000-00002
- Wahyudi H, Reynolds AA, Li Y, Owen SC, Yu SM. Targeting collagen for diagnostic imaging and therapeutic delivery. J Control Release. 2016;240:323-331. doi:10.1016/j.jconrel.2016.01.007